Literature DB >> 24671570

Functional expression of a single-chain antibody fragment against human epidermal growth factor receptor 2 (HER2) in Escherichia coli.

Vajihe Akbari1, Hamid Mir Mohammad Sadeghi, Abbas Jafrian-Dehkordi, Daryoush Abedi, C Perry Chou.   

Abstract

The human epidermal growth factor receptor (HER) family plays an important role in cell growth and signaling and alteration of its function has been demonstrated in many different kinds of cancer. Receptor dimerization is necessary for the HER signal transduction pathway and tyrosine kinase activity. Recently, several monoclonal antibodies have been developed to directly interfere with ligand-HER receptor binding and receptor dimerization. A single chain variable fragment (ScFv) is a valuable alternative to an intact antibody. This report describes the production and purification of an ScFv specific for domain II of the HER2 receptor in Escherichia coli BL21 (DE3) cytoplasm. The majority of expressed of anti-her2his-ScFv protein was produced as inclusion bodies. A Ni-NTA affinity column was used to purify the anti-her2his-ScFv protein. The molecular weight of anti-her2his-ScFv protein was estimated to be approximately 27 kDa, as confirmed by SDS-PAGE and Western blotting assay. The anti-her2his-ScFv showed near 95 % purity and reached a yield of approximately 29 mg/l in flask fermentation. The purified anti-her2his-ScFv showed its biological activity by binding to HER2 receptor on the surface of BT-474 cells. This ScFv may be a potential pharmaceutical candidate for targeting tumour cells overexpressing HER2 receptor.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24671570     DOI: 10.1007/s10295-014-1437-0

Source DB:  PubMed          Journal:  J Ind Microbiol Biotechnol        ISSN: 1367-5435            Impact factor:   3.346


  49 in total

1.  Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein.

Authors:  Paul J Yazaki; Thewodros Kassa; Chia-wei Cheung; Desiree M Crow; Mark A Sherman; James R Bading; Anne-Line J Anderson; David Colcher; Andrew Raubitschek
Journal:  Nucl Med Biol       Date:  2008-02       Impact factor: 2.408

2.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.

Authors:  T Yokota; D E Milenic; M Whitlow; J Schlom
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

3.  Cloning and optimization of induction conditions for mature PsaA (pneumococcal surface adhesin A) expression in Escherichia coli and recombinant protein stability during long-term storage.

Authors:  Ariane Leites Larentis; Ana Paula Corrêa Argondizzo; Gabriela dos Santos Esteves; Ellen Jessouron; Ricardo Galler; Marco Alberto Medeiros
Journal:  Protein Expr Purif       Date:  2011-03-06       Impact factor: 1.650

4.  Cell-free expression of two single-chain monoclonal antibodies against lysozyme: effect of domain arrangement on the expression.

Authors:  H Merk; W Stiege; K Tsumoto; I Kumagai; V A Erdmann
Journal:  J Biochem       Date:  1999-02       Impact factor: 3.387

5.  Generation and characterization of new HER2 monoclonal antibodies.

Authors:  Flávia Aleixo Vasconcellos; Pedro Bandeira Aleixo; Simone Cardozo Stone; Fabricio Rochedo Conceição; Odir Antônio Dellagostin; José Antonio Guimarães Aleixo
Journal:  Acta Histochem       Date:  2012-08-15       Impact factor: 2.479

6.  High-level accumulation of a recombinant antibody fragment in the periplasm of Escherichia coli requires a triple-mutant (degP prc spr) host strain.

Authors:  Christina Chen; Brad Snedecor; Julie C Nishihara; John C Joly; Nancy McFarland; Dana C Andersen; John E Battersby; Kathleen M Champion
Journal:  Biotechnol Bioeng       Date:  2004-03-05       Impact factor: 4.530

7.  Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting.

Authors:  Tove Olafsen; Giselle J Tan; Chia-Wei Cheung; Paul J Yazaki; Jinha M Park; John E Shively; Lawrence E Williams; Andrew A Raubitschek; Michael F Press; Anna M Wu
Journal:  Protein Eng Des Sel       Date:  2004-06-08       Impact factor: 1.650

8.  An intrinsically stable antibody scFv fragment can tolerate the loss of both disulfide bonds and fold correctly.

Authors:  A Wörn; A Plückthun
Journal:  FEBS Lett       Date:  1998-05-15       Impact factor: 4.124

9.  Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer.

Authors:  A Berchuck; A Kamel; R Whitaker; B Kerns; G Olt; R Kinney; J T Soper; R Dodge; D L Clarke-Pearson; P Marks
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

10.  Recombinant early secreted antigen target 6 protein as a skin test antigen for the specific detection of Mycobacterium tuberculosis infection.

Authors:  X Wu; L Zhang; J Zhang; C Zhang; L Zhu; Y Shi
Journal:  Clin Exp Immunol       Date:  2008-04       Impact factor: 4.330

View more
  9 in total

1.  Anti-HER2 scFv Expression in Escherichia coli SHuffle®T7 Express Cells: Effects on Solubility and Biological Activity.

Authors:  Maryam Ahmadzadeh; Farzaneh Farshdari; Leila Nematollahi; Mahdi Behdani; Elham Mohit
Journal:  Mol Biotechnol       Date:  2020-01       Impact factor: 2.695

2.  Expression of V(H)-linker-V(L) orientation-dependent single-chain Fv antibody fragment derived from hybridoma 2E6 against aflatoxin B1 in Escherichia coli.

Authors:  Aiping Liu; Yang Ye; Weifeng Chen; Xiaohong Wang; Fusheng Chen
Journal:  J Ind Microbiol Biotechnol       Date:  2014-12-25       Impact factor: 3.346

3.  Evaluation of soluble expression of recombinant granulocyte macrophage stimulating factor (rGM-CSF) by three different E. coli strains.

Authors:  Sina Soheili; Ali Jahanian-Najafabadi; Vajihe Akbari
Journal:  Res Pharm Sci       Date:  2020-07-03

4.  Different strategies for expression and purification of the CT26-poly-neoepitopes vaccine in Escherichia coli.

Authors:  Zahra Movahed; Elham Sharif; Maryam Ahmadzadeh; Navid Nezafat; Hoda Jahandar; Elham Mohit
Journal:  Mol Biol Rep       Date:  2022-01-20       Impact factor: 2.316

5.  Optimization of a single-chain antibody fragment overexpression in Escherichia coli using response surface methodology.

Authors:  V Akbari; H Mir Mohammad Sadeghi; A Jafarian-Dehkordi; C Perry Chou; D Abedi
Journal:  Res Pharm Sci       Date:  2015 Jan-Feb

6.  The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab.

Authors:  Jung Won Shin; Soohyun Kim; Suji Ha; Byungsan Choi; Seongyeong Kim; Seock-Ah Im; Tae-Young Yoon; Junho Chung
Journal:  Biomolecules       Date:  2019-10-19

7.  Effects of variable domain orientation on anti-HER2 single-chain variable fragment antibody expressed in the Escherichia coli cytoplasm.

Authors:  İlkay Koçer; Emily C Cox; Matthew P DeLisa; Eda Çelik
Journal:  Biotechnol Prog       Date:  2020-11-20

8.  A single-domain antibody-linked Fab bispecific antibody Her2-S-Fab has potent cytotoxicity against Her2-expressing tumor cells.

Authors:  Aifen Li; Jieyu Xing; Li Li; Changhua Zhou; Bin Dong; Ping He; Qing Li; Zhong Wang
Journal:  AMB Express       Date:  2016-04-26       Impact factor: 3.298

Review 9.  Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments.

Authors:  Annamaria Sandomenico; Jwala P Sivaccumar; Menotti Ruvo
Journal:  Int J Mol Sci       Date:  2020-08-31       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.